NP (CTD) COVID-19
for SARS-CoV-2

NP (CTD) (COVID-19) is the nucleoprotein C-terminal domain of the coronavirus nucleocapsid (N). This recombinant antigen has been prepared by expressing aa 212 to 417 from de nucleoprotein of SARS-CoV-2. Coronavirus nucleocapsid (N) protein is a highly phosphorylated protein which not only is responsable for construction of the ribonucleoprotein complex by interacting with the viral genome and regulating the synthesis of viral RNA and protein, but also serves as a potent immunogen that induces humoral and cellular immunity. The nucleoprotein is one of the major antigens of the SARS-CoV-2 and there are abundant antigenic sites predicted in this protein. Compared with other viral structural proteins, the low variation rate of the N protein with regards to its size suggests its importance to the survival of the virus.

References of Recombinant antigen NP (CTD) COVID-19

Folletos

• Rekom Biotech catalogue
• Recombinant proteins for in vitro diagnosis of human infectious diseases
• Recombinant antigens for diagnosis of COVID-19

Videos

• How to reconsitute lyophizated vials

Evaluaciones

• Nucleoprotein and spike glycoprotein, a combination of two quite different antigens for COVID-19 in vitro diagnostic

Otros

• Rekom Biotech's antigen for COVID-19 is ready to support India for rapid and effective detection of this disease
• Vaccination vs Natural infection. A diagnostic challenge in COVID-19 asymptomatic patients, when the immunity profile is not known.
• Returning to normal life despite COVID-19
• Detection of the new coronavirus disease 2019 (COVID-19) by rapid serodiagnostic assays

Related proteins